Navigation Links
Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
Date:2/22/2009

New procedure could offer a safer, more convenient treatment for spine tumors

LAS VEGAS, Feb. 22 /PRNewswire-USNewswire/ -- For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission. Her cousin died from the disease several years ago. Dr. Keyak still remembers the incredible pain her cousin experienced when the cancer spread to her spine. A new study released by Dr. Keyak and her colleagues at the University of California, Irvine, shows patients whose breast cancer metastasizes to their spines may have a better option than the usual treatment, which can include up to 10 sessions of radiation therapy. The study looked at alternative -- injecting radioactive bone cement into the vertebral body -- with promising results.

The UCI researchers collaborated with a colleague from St. Jude Heritage Medical Group in Fullerton, Calif., to investigate this technique. Dr. Keyak is presenting the team's findings in the paper "Feasibility of Using Radioactive Bone Cement to Treat Vertebral Metastases" during the 55th Annual Meeting of the Orthopaedic Research Society, Feb. 22-25, 2009, in Las Vegas.

"With further development, this technology may yield a clinically feasible procedure that would eliminate the need for 10 radiation therapy sessions, making it more convenient for the patient," says Dr. Keyak, an associate professor in UCI's department of orthopaedic surgery. "This procedure would also deliver a higher dose to the bone metastases and a lower dose to the spinal cord and other normal tissues than conventional external beam radiation therapy, potentially improving the clinical outcome," she explains. "The negligible dose to the spinal cord would also make it possible to treat recurrent spinal tumors in patients who have already received the maximum allowable radiation dose to the spinal cord."

According to the American Cancer Society, almost 185,000 people in the United States -- mainly women -- were diagnosed with invasive breast cancer in 2008. In addition, a study published in the journal Spine showed that, of those patients whose breast cancer metastasizes, almost 75 percent develop spine tumors.

Spinal metastases can cause pain and vertebral collapse. And, due to the proximity of the spinal cord and nerves, those tumors can lead to serious neurological complications. Conventional treatment often occurs in two phases:

  1. A surgical procedure (vertebroplasty or kyphoplasty) in which bone cement is injected into the body to stabilize the bone
  2. Subsequent external beam radiation therapy (or EBRT) to control tumor growth

The effectiveness of EBRT for spinal metastases is limited because the spinal cord restricts the dose of radiation that can be safely delivered. In addition, EBRT is typically provided in multiple sessions to reduce toxicity to the spinal cord, making treatment inconvenient for the patient.

The therapy investigated by Dr. Keyak and her colleagues would combine the two treatment phases into one procedure by mixing a radioactive compound with the injected cement. A single procedure using this radioactive bone cement would provide structural reinforcement to the bone while simultaneously irradiating the tumor from within (i.e., vertebral brachytherapy). Results of the study showed that a therapeutic dose of radiation would reach the intended bone without undue risk to tissue beyond a certain range (such as the spinal cord).

Once the results are validated, subsequent studies will look at the following:

  • Refining the choice of radioisotope(s), amount of activity and geographic distribution of the cement
  • Sensitivity of the radiation dose distribution to variations in bone size, density and tumor type; differences in bone cement formulations; and other factors associated with a potential clinical application

An abstract of the study is available online at http://www.ors.org/web/Media.asp.

For more information about the Orthopaedic Research Society, visit the ORS Web site (http://www.ors.org/web/about_the_ors/welcome.asp).


'/>"/>
SOURCE Orthopaedic Research Society
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
2. Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
3. Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
4. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
8. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
9. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
10. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
11. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):